Abstracts tagged "immunity"

Abstract Number: 384 • 2017 ACR/ARHP Annual Meeting
Protection Against Hepatitis B in Immunocompromised Pediatric Rheumatology and Gastroenterology Patients
Najla Aljaberi¹, Emily A. Smitherman², Enas Ghulam³, Allen Watts², Dana MH Dykes⁴ and Jennifer L. Huggins⁵, ¹Pediatric rheumatology, Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Environmental health and biostatistics, Department of Environmental Health, University of Cincinnati, Division of Biostatistics and Epidemiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Gastroenterology, Hepatology, and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Hepatitis B infection remains a significant public health challenge, particularly for patients on chronic immunosuppressive therapy, due to a considerable mortality risk associated with…
Abstract Number: 757 • 2017 ACR/ARHP Annual Meeting
Plasmacytoid Dendritic Cells Activated through TLR8 Promote Systemic Sclerosis
Marie-Dominique Ah Kioon¹, Claudio Tripodo², Alexandra Morquette³, Robert F. Spiera³, Jessica K. Gordon³ and Franck J. Barrat¹, ¹Autoimmunity and Inflammation Program, Hospital for Special Surgery, New York, NY, ²Department of Health Science, Human Pathology, tumor immunology unit, Palermo, Italy, ³Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Plasmacytoid Dendritic Cells (PDCs) are the key cell type mediating TLR-induced inflammation in several autoimmune diseases such as lupus, dermatomyositis, lichen sclerosus and cutaneous…
Abstract Number: 2415 • 2017 ACR/ARHP Annual Meeting
Immunogenicity and Persistence of a Prime-Boost Re-Vaccination Strategy for Pneumococcal Vaccines (13-Valent Pneumococcal Conjugate Vaccine + 23-Valent Pneumococcal Polysaccharide Vaccine) in Patients with Rheumatoid Arthritis: A Pilot Study
Mathilde Bahuaud¹, Constance BEAUDOUIN², Anna Molto³, Odile Launay⁴, Frederic Batteux⁵ and Maxime Dougados⁶, ¹Université Paris Descartes, Sorbonne Paris Cité AP-HP, Département d’Immunologie Biologique, Groupe Hospitalier Cochin Broca Hôtel-Dieu, Paris, France, Paris, France, ²Cochin Hospital, APHP, Rheumatology B, Paris, France, ³Hôpital Cochin, Department of Rheumatology, Paris Descartes University, Paris, France, ⁴Université Paris Descartes, Sorbonne Paris Cité AP-HP, Groupe Hospitalier Cochin Broca Hôtel-Dieu, Fédération d'Infectiologie, Paris, France; Inserm, F-CRIN I-REIVAC., Paris, France, ⁵Immunology, APHP Hopital Cochin, Paris, France, ⁶Department of Rheumatology, Paris Descartes University, Hôpital Cochin, Paris, France
Background/Purpose: Patients with rheumatoid arthritis (RA) are at an increased risk of some serious vaccine-preventable infections, like Pneumococcal infections. Since 2013, French vaccine recommendations committee…
Abstract Number: 2700 • 2017 ACR/ARHP Annual Meeting
Fra-2 Overexpression Leads to Systemic Autoimmunity By Affecting IL2 Dependent Treg Homeostasis
Florian Renoux¹, Mara Stellato¹, Daniela Impellizzieri², Alexander Vogetseder³, Przemyslaw Blyszczuk¹, Riyun Huang⁴, Arun Subramaniam⁵, Clara Dees⁶, Jörg Distler⁷, Gabriela Kania¹, Onur Boyman² and Oliver Distler⁸, ¹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Division of Clinical Immunology, University Hospital Zurich, Zurich, Switzerland, ³Department of Pathology, Cantonal Hospital Lucerne, Lucerne, Switzerland, ⁴Immune Mediated Diseases, Sanofi-Genzyme, Framingham, MA, ⁵Sanofi-Genzyme, Framingham, MA, ⁶Department of Internal Medicine 3 and Institute for Clinical Immunology,, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁷Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁸Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Fos-related antigen 2 (Fra-2) is a transcription factor belonging to the Fos family proteins which is part of the AP-1 transcription factor complex. We…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].